Vipergen ApS

We are now live in Drug Discovery Chemistry Europe in Barcelone. Excited to be there! The picture is from the Vipergen poster on screening for inhibitors of the p53-MDM2 interaction. The technology is also described on https://lnkd.in/dgwQmfUG

We are excited to participate in the upcoming conference, Drug Discovery Chemistry in Barcelona, Spain on December 3-5. Leif Kongskov Larsen, PhD, will present poster # P30 entitled: DELS in Cells: Screening of DNA Encoded Libraries for PPI Inhibitors, and will give a talk about the technology that enables us to screen DNA encoded Libraries in Cells. You can see more about how screening DELs in a living cell in a multiplexing format enables us to directly discover PPI inhibitors at https://lnkd.in/dgwQmfUG Vipergen is a world-leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies and is the first and only company capable of screening DELs inside a living cell. See you soon! #DrugDiscovery #DNAEncodedLibrary

SARomics Biostructures AB and Vipergen ApS partner to offer enhanced hit and lead identification services based on our complementary technology platforms. By combining Vipergen’s DEL screening technologies with SARomics structural biology capabilities, we will enhance our drug discovery services by offering expedited hit identification and lead generation. See https://lnkd.in/dUA8U3Rk for more details. #hitidentification #drugdiscovery #del #crystallography

We are now live at Targeting Protein Degradation 4 at Cranfield University, UK Come visit Rico Gerup Petersen, PhD, at his poster entitled “DELs in Cells: Direct Screening for Molecular Glue". He will be happy to discuss the poster - and to discuss the our technology for screening DELs in living cells. You can see more about how screening DELs in a living cell in a multiplexing format enables us to directly discover molecular glues at https://lnkd.in/d8rC8BCM Vipergen is a world-leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies and is the first an d only company capable of screening DELs inside a living cell.

We are excited to participate in the upcoming conference, Targeting Protein Degradation 4 at Cranfield University, UK on October 15-16 Rico Gerup Petersen, PhD, will present a poster and give a flash presentation, entitled “DELs in Cells: Direct Screening for Molecular Glue" You can see more about how screening DELs in a living cell in a multiplexing format enables us to directly discover molecular glues at https://lnkd.in/d8rC8BCM Vipergen is a world-leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies and is the first and only company capable of screening DELs inside a living cell. See you soon!

We are now live at the Discovery on Target 2024 Conference with our strategic partner, Aurigene Pharmaceutical Services Limited Leif Kongskov Larsen, Ph.D., Director, Biology at Vipergen ApS is attending the conference together with Jenny Yip, Sr. Director, Business Development, Biologics, and Sarah Lafferty, Sr. Director, Business Development, Discovery from Aurigene Pharmaceutical Services Limited. They are available at booth #424 and would love to discuss your molecule journey and how DEL (DNA-encoded Library) technology together with Aurigene's end-to-end discovery offerings can help your project go from idea to market faster. Leif presents a poster, #A54, entitled: “DELs in Cells: Direct Screening of DNA Encoded Libraries for PPI Inhibitors”, showing a case study of screening for p53-MDM2 PPI inhibitors in a living cell. You can find more about our libraries and technologies at www.vipergen.com. Vipergen ApS is a world-leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies and is the first and only company capable of screening DELs inside a living cell. Aurigene Pharmaceutical Services Limited is a global CRDMO offering a wide variety of solutions for integrated drug discovery, including CADD / AI, chemistry, in vitro screening, DMPK, in vivo pharmacology, microbiology, and toxicology, along with CDMO services. #pharmaceuticals #biotechnology #drugdiscovery

We are excited to participate in the upcoming Discovery on Target 2024 with our strategic partner, Aurigene Pharmaceutical Services Limited Meet us at Poster A54, or at Booth #424 from September 30 to October 3 at the Sheraton Boston, where we will be available to discuss the latest advancements in DEL screening in living cells as well as Aurigene's capabilities in biologics and small molecules. On the thought leadership front, Leif Kongskov Larsen, PhD, will present a poster, A54, entitled “DELs in Cells: Direct Screening of DNA Encoded Libraries for PPI Inhibitors”. Vipergen is a world-leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies and is the first and only company capable of screening DELs inside a living cell. With Aurigene's comprehensive capability to support from discovery to commercial scale cGMP manufacturing, expertise across diverse biologics modalities, and small molecules discovery in both chemistry and biology, they are well suited to taking your from molecule from lab to market faster. Write us at [email protected] to book a meeting with our experts attending the DOT conference in Boston. See you soon!

Vipergen now introduces DELs in Cells - Snap An easy, fast, and affordable way to get an early lead. DELs in Cells - Snap runs in two stages. Stage 1: You provide the amino acid sequence of your target protein, and we test for successful protein expression in a living cell. You will then within one month receive a report and a go-no-go recommendation. Stage 2: After your 'Go', we will screen your target in a living cell with a 500 million member high diversity/high quality DEL. You will then within one month receive a report and chemical structure information for 25 top hits. Virtues: Never been easier Pay as you go - two payments Low cost Standardized process High success rates No need for purified target protein Screen under physiologically relevant conditions in a living cell Hit exclusivity https://lnkd.in/dUkP3XmG

We are hiring! Looking for a senior scientist (chemist) with the following key responsibilities: » Continued development of DNA-encoded libraries and support of the synthesis thereof. » Analysis of complex screening data and reporting screening results to external partners. See the full description here: https://lnkd.in/dRjXKUMT Deadline for applications is September 30th.

We are now live at the EFMC-ISMC International Symposium on Medicinal Chemistry with our strategic partner, Aurigene Pharmaceutical Services Limited Rico Gerup Petersen, PhD, Senior Scientist at Vipergen ApS is attending this symposium together with Sangamesh Badiger, Tania Dey, and ASHWINI KUMAR KAPOOR from Aurigene Pharmaceutical Services Limited. They are available at booth #51 and would love to discuss your molecule journey and how DEL (DNA-encoded Library) technology together with Aurigene's end-to-end discovery offerings can help your project go from idea to market faster. Rico presents a poster, #423, entitled: “GENERATION OF HIGH-QUALITY AND DIVERSE DNA-ENCODED LIBRARIES”. You can find more about our libraries and technologies at www.vipergen.com   Vipergen ApS is a world-leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies and is the first and only company capable of screening DELs inside a living cell. Aurigene Pharmaceutical Services Limited is a global CRDMO offering a wide variety of solutions for integrated drug discovery, including CADD / AI, chemistry, in vitro screening, DMPK, in vivo pharmacology, microbiology, and toxicology, along with CDMO services. #pharmaceuticals #biotechnology #drugdiscovery